Falla cardíaca crónica etapa B
DOI:
https://doi.org/10.17533/udea.iatreia.26739Palabras clave:
enfermedad coronaria, guía, insuficiencia cardíacaResumen
Introducción: clásicamente se ha definido la falla cardíaca como un síndrome clínico. La detección temprana de los pacientes en alto riesgo de desarrollarla y de aquellos con disfunción ventricular asintomática, que por definición no cumplen los criterios, se ha convertido en una estrategia eficaz de tratamiento, por lo que han sido incluidos en la clasificación y en las guías de práctica clínica.
Metodología: para la creación de la guía de práctica clínica (GPC) basada en la evidencia se siguieron los pasos definidos en la Guía Metodológica para la Elaboración de Guías de Práctica Clínica con Evaluación Económica en el Sistema General de Seguridad Social en Salud del Ministerio de Salud y Protección Social de Colombia.
Resultados: se establecen las recomendaciones de tratamiento de la falla cardíaca con disfunción ventricular izquierda asintomática.
Conclusión: algunas estrategias terapéuticas cambian el pronóstico de los pacientes con falla cardíaca en estadio B; de ahí la importancia de la detección temprana en pacientes de alto riesgo y la instauración precoz del tratamiento.
Descargas
Citas
(1.) Yang H, Negishi K, Otahal P, Marwick TH. Clinical prediction of incident heart failure risk: a systematic review and meta-analysis. Open Heart. 2015 Apr;2(1):e000222. DOI 10.1136/openhrt-2014-000222.
(2.) Ajello L, Coppola G, Corrado E, La Franca E, Rotolo A, Assennato P. Diagnosis and treatment of asymptomatic left ventricular systolic dysfunction after myocardial infarction. ISRN Cardiol. 2013;2013:731285. DOI 10.1155/2013/731285.
(3.) Verdecchia P, Angeli F, Gattobigio R, Sardone M, Porcellati C. Asymptomatic left ventricular systolic dysfunction in essential hypertension: prevalence, determinants, and prognostic value. Hypertension. 2005 Mar;45(3):412-8.
(4.) Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med. 1996 Jun;334:1649-55. DOI 10.1056/NEJM199606203342507.
(5.) Tanai E, Frantz S. Pathophysiology of Heart Failure. Compr Physiol. 2015 Dec;6(1):187-214. DOI 10.1002/cphy.c140055.
(6.) Gring CN, Francis GS. A hard look at angiotensin receptor blockers in heart failure. J Am Coll Cardiol. 2004 Nov;44(9):1841-6.
(7.) Heran BS, Musini VM, Bassett K, Taylor RS, Wright JM. Angiotensin receptor blockers for heart failure. Cochrane Database Syst Rev. 2012 Apr;(4):CD003040. DOI 10.1002/14651858.CD003040.pub2.
(8.) ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100 000 patients in randomized trials. Circulation. 1998 Jun;97(22):2202-12.
(9.) Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep;327(10):669-77.
(10.) Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993 Oct342(8875):821-8.
(11.) Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995 Dec;333(25):1670-6.
(12.) The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991 Aug;325(5):293-302.
(13.) The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992 Sep;327(10):685-91. Erratum in: N Engl J Med. 1992 Dec;327(24):1768.
(14.) Flather MD, Yusuf S, Køber L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-Ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000 May;355(9215):1575-81.
(15.) Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med. 2001 Dec;345(23):1667-75.
(16.) Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003 Sep;362(9386):772-6.
(17.) Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, et al. Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group. Circulation. 1995 Feb;91(3):691-7.
(18.) Mazayev VP, Fomina IG, Kazakov EN, Sulimov VA, Zvereva TV, Lyusov VA, et al. Valsartan in heart failure patients previously untreated with an ACE inhibitor. Int J Cardiol. 1998 Aug;65(3):239-46.
(19.) Riegger GA, Bouzo H, Petr P, Münz J, Spacek R, Pethig H, et al. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators. Circulation. 1999 Nov;100(22):2224-30.
(20.) Matsumori A; Assessment of Response to Candesartan in Heart Failure in Japan (ARCH-J) Study Investigators. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail. 2003 Oct;5(5):669-77. Erratum in: Eur J Heart Fail. 2004 Jun;6(4):523.
(21.) Mitrovic V, Willenbrock R, Miric M, Seferovic P, Spinar J, Dabrowski M, et al. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure. Am Heart J. 2003 Mar;145(3):E14.
(22.) Sharma D, Buyse M, Pitt B, Rucinska EJ. Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. Losartan Heart Failure Mortality Meta-analysis Study Group. Am J Cardiol. 2000 Jan;85(2):187-92.
(23.) Granger CB, Ertl G, Kuch J, Maggioni AP, McMurray J, Rouleau JL, et al. Randomized trial of candesartan cilexitil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J. 2000 Apr;139(4):609-17. DOI 10.1016/S0002-8703(00)90037-1.
(24.) Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997 Mar;349(9054):747-52.
(25.) Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000 May;355(9215):1582-7.
(26.) Willenheimer R, Helmers C, Pantev E, Rydberg E, Löfdahl P, Gordon A, et al. Safety and efficacy of valsartan versus enalapril in heart failure patients. Int J Cardiol. 2002 Oct;85(2-3):261-70.
(27.) Dunselman PH; Replacement of Angiotensin Converting Enzyme Inhibition (REPLACE) Investigators. Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) investigators. Int J Cardiol. 2001 Feb;77(2-3):131-8; discussion 139-40.
(28.) Dickstein K, Chang P, Willenheimer R, Haunsø S, Remes J, Hall C, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol. 1995 Aug;26(2):438-45.
(29.) Lang RM, Elkayam U, Yellen LG, Krauss D, McKelvie RS, Vaughan DE, et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators. J Am Coll Cardiol. 1997 Oct;30(4):983-91.
(30.) McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003 Sep;362(9386):767-71.
(31.) McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 1999 Sep;100(10):1056-64.
(32.) Hamroff G, Katz SD, Mancini D, Blaufarb I, Bijou R, Patel R, et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation. 1999 Mar;99(8):990-2.
(33.) Tonkon M, Awan N, Niazi I, Hanley P, Baruch L, Wolf RA, et al. A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Irbesartan Heart Failure Group. Int J Clin Pract. 2000 Jan-Feb;54(1):11-4, 16-8.
(34.) Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000 Mar;160(5):685-93.
(35.) Desai AS, Swedberg K, McMurray JJ, Granger CB, Yusuf S, Young JB, et al. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. J Am Coll Cardiol. 2007 Nov;50(20):1959-66.
(36.) Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000 Feb;355(9204):637-45.
(37.) Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HM. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med. 2007 Oct;167(18):1930-6.
(38.) Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001 May;357(9266):1385-90.
(39.) Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981 Apr;304(14):801-7.
(40.) Gilbert EM. Cost-effectiveness of beta-blocker treatment in heart failure. Rev Cardiovasc Med. 2002;3 Suppl 3:S42-7.
(41.) Díez-Manglano J. [Economic analysis of the treatment of heart failure with beta-blockers]. Med Clin (Barc). 2013 Sep;141(6):265-70. DOI 10.1016/j.medcli.2013.02.011.
(42.) Solomon SD, Zelenkofske S, McMurray JJ, Finn PV, Velazquez E, Ertl G, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005 Jun;352(25):2581-8. Erratum in: N Engl J Med. 2005 Aug;353(7):744.
(43.) Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med. 2001 Nov;345(20):1473-82.
(44.) Theuns DA, Smith T, Hunink MG, Bardy GH, Jordaens L. Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or nonischaemic heart disease: a systematic review and meta-analysis. Europace. 2010 Nov;12(11):1564-70. DOI 10.1093/europace/euq329.
(45.) Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996 Dec;335(26):1933-40.
(46.) Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med. 1997 Nov;337(22):1569-75.
(47.) Bänsch D, Antz M, Boczor S, Volkmer M, Tebbenjohanns J, Seidl K, et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation. 2002 Mar;105(12):1453-8.
(48.) Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002 Mar;346(12):877-83.
(49.) Strickberger SA, Hummel JD, Bartlett TG, Frumin HI, Schuger CD, Beau SL, et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT. J Am Coll Cardiol. 2003 May;41(10):1707-12.
(50.) Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004 May;350(21):2151-8.
(51.) Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004 Dec;351(24):2481-8.
(52.) Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005 Jan;352(3):225-37. Erratum in: N Engl J Med. 2005 May;352(20):2146.
(53.) Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009 Oct;361(15):1427-36. DOI 10.1056/NEJMoa0901889.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2017 Iatreia
Esta obra está bajo una licencia internacional Creative Commons Atribución-CompartirIgual 4.0.
Los artículos publicados en la revista están disponibles para ser utilizados bajo la licencia Creative Commons, específicamente son de Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional.
Los trabajos enviados deben ser inéditos y suministrados exclusivamente a la Revista; se exige al autor que envía sus contribuciones presentar los formatos: presentación de artículo y responsabilidad de autoría completamente diligenciados.
